Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab.
Bueno-Muiño C, Echavarría I, López-Tarruella S, Roche-Molina M, Del Monte-Millán M, Massarrah T, Jerez Y, Ayala de la Peña F, García-Sáenz JÁ, Moreno F, Rodríguez-Lescure Á, Malón-Giménez D, Ballesteros García AI, Marín-Aguilera M, Galván P, Brasó-Maristany F, Waks AG, Tolaney SM, Mittendorf EA, Vivancos A, Villagrasa P, Parker JS, Perou CM, Paré L, Villacampa G, Prat A, Martín M. Bueno-Muiño C, et al. Among authors: lopez tarruella s. JAMA Oncol. 2023 Jun 1;9(6):841-846. doi: 10.1001/jamaoncol.2023.0187. JAMA Oncol. 2023. PMID: 37103916 Free PMC article.
New target-based agents involve new clinical trial designs.
Bueno Muíño C, García-Sáenz JA, López Tarruella S, Rodríguez Lajustica L, Díaz-Rubio E. Bueno Muíño C, et al. Clin Transl Oncol. 2006 Aug;8(8):581-7. doi: 10.1007/s12094-006-0063-3. Clin Transl Oncol. 2006. PMID: 16952846 Review.
Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review.
García-Sáenz JA, Custodio A, Casado A, Vidart JA, Coronado PJ, Martín M, López-Tarruella S, Puente J, Fernández C, Díaz-Rubio E. García-Sáenz JA, et al. Clin Transl Oncol. 2011 Feb;13(2):121-32. doi: 10.1007/s12094-011-0629-6. Clin Transl Oncol. 2011. PMID: 21324801 Review.
Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.
Martin M, Romero A, Cheang MC, López García-Asenjo JA, García-Saenz JA, Oliva B, Román JM, He X, Casado A, de la Torre J, Furio V, Puente J, Caldés T, Vidart JA, Lopez-Tarruella S, Diaz-Rubio E, Perou CM. Martin M, et al. Breast Cancer Res Treat. 2011 Jul;128(1):127-36. doi: 10.1007/s10549-011-1461-y. Epub 2011 Apr 5. Breast Cancer Res Treat. 2011. PMID: 21465170 Clinical Trial.
73 results